Article

Advanced Medical Optics viscosurgical device receives FDA approval

Advanced Medical Optics (AMO) announced that the FDA has granted premarket approval of a clear dispersive ophthalmic viscosurgical device (OVD) (Healon D) for use as a surgical aid in cataract extraction, IOL implantation, corneal transplant, and glaucoma filtration surgery.

Key Points

Santa Ana, CA-Advanced Medical Optics (AMO) announced that the FDA has granted premarket approval of a clear dispersive ophthalmic viscosurgical device (OVD) (Healon D) for use as a surgical aid in cataract extraction, IOL implantation, corneal transplant, and glaucoma filtration surgery.

Due to its low molecular weight, the OVD coats the cornea and remains in place throughout the entire surgical process. The latex-free OVD has a lower viscosity, providing ideal lubrication of IOL insertion systems, according to the company.

The FDA approval of the OVD also allows AMO to introduce two new dual-pack ophthalmic viscosurgical systems that contain the OVD as part of convenient combination packs.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
© 2025 MJH Life Sciences

All rights reserved.